drugset / Trial / NCT02279823

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823

Phase 2 Completed 95 enrolled Intrepid Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

In this proof-of-concept study, the safety and efficacy of a solution formulation will be investigated in male subjects with androgenetic alopecia (AGA) after twice daily application for up to 26 weeks.

Timeline

Start
2014-10
Primary completion
2015-12
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Clascoterone Small molecule 5 % Topical
Comparator Minoxidil Small molecule 5 % Topical

Indications